

## ICMJE DISCLOSURE FORM

Date: February 25<sup>th</sup>, 2023

Your Name: Wolfgang M. Brueckl

Manuscript Title: dynamic change of CD8- T cell: immunotherapy fate tell?

Manuscript number (if known): TLCR-23-139

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	The author received funding for the present manuscript from the W. Lutz Stiftung, Nuremberg, Germany.	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>  X  </u> None	
3	Royalties or licenses	<u>  X  </u> None	

4	Consulting fees	<input type="checkbox"/> _X_ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca	lecture fees, educational events, personal
		Boehringer	lecture fees, educational events, personal
		Novartis	lecture fees, personal
		MSD	lecture fees, personal
		BMS	lecture fees, personal
		Roche	lecture fees, educational events, personal
		Lilly	Lecture fees, educational events, personal
		Pfizer	Lecture fees, educational events, personal
6	Payment for expert testimony	<input type="checkbox"/> _X_ None	
7	Support for attending meetings and/or travel	Boehringer	Congress fees, personal
		AstraZeneca	Congress fees, personal
		Roche Pharma	Congress fees, personal
8	Patents planned, issued or pending		EP21183549.1
			method for predicting a clinical response towards an immune checkpoint inhibitor based on pretreatment therewith
9	Participation on a Data Safety Monitoring Board or Advisory Board	AstraZeneca	Adboard, personal
		Boehringer	Adboard, personal
		Novartis	Adboard, personal
		MSD	Adboard, personal
		Lilly Pharma	Adboard, personal
		BMS	Adboard, personal
		Roche	Adboard, personal
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> _X_ None	
11	Stock or stock options	<input type="checkbox"/> _X_ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	<input type="checkbox"/> _X_ None	

Please summarize the above conflict of interest in the following box:

The author received funding for the present manuscript from the W. Lutz Stiftung, Nuremberg, Germany. The author received honoraria for lectures or educational events from AstraZeneca, Boehringer, Novartis, MSD, BMS, Lilly, Pfizer and Roche. The author received support for attending meetings and/or travel from Boehringer, Roche and AstraZeneca. The author served on advisory board of Astra Zeneca, Boehringer, Novartis, MSD, Lilly Pharma, BMS, and Roche. The author received equipment, material, drugs, medical writing, gifts or other services from Boehringer for medical writing. The author's patent application EP21183549.1 (method for predicting a clinical response towards an immune checkpoint inhibitor based on pretreatment therewith) was filed with regard to the results of this study.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**